Since last September, the Hong Kong stock market's innovative drug sector has shifted from its previous bull market state, entering a volatile downtrend, with a particularly persistent decline following mid-April this year.
This has directly led to the Hang Seng Healthcare Index falling consistently since mid-April.
From April 16th to the present, the index has dropped by more than 25%.
On the same day, April 16th, LEADS BIOLABS-B (09887) saw its intraday share price reach HK$97.50, setting a new post-listing high.
Subsequently, the company's stock price corrected alongside the broader Hong Kong healthcare sector.
By June 25th, the intraday low had reached HK$47.62, representing a drop of over 50% from the previous high and nearing its 2026 year-to-date low.
This level of correction means LEADS BIOLABS-B has given back all the gains achieved since its inclusion in the Stock Connect program.
However, the stock price does not yet appear to have found a stable bottom.
With the completion of its H-share full circulation and an impending early shareholder lock-up expiration, whether LEADS BIOLABS-B can withstand the resulting selling pressure is a key focus for investors.
Key Catalysts and Market Movements
Looking at a longer timeline, LEADS BIOLABS-B's stock price surged 87.71% between March and April this year, driven by a combination of pipeline breakthroughs and improved market liquidity.
Firstly, clinical progress of its core product, LBL-024, was the most critical driver.
Company announcements indicated its PD-L1/4-1BB bispecific antibody successfully entered the expansion phase of a Phase II study for biliary tract cancer, while a Phase II study for esophageal squamous cell carcinoma enrolled its first patient.
These developments strengthened expectations for the drug to become the first globally approved 4-1BB targeted therapy, with a Biologics License Application for extrapulmonary neuroendocrine carcinoma planned for Q3 2026.
Secondly, inclusion in the Hong Kong Stock Connect program triggered a qualitative change in fund flows.
Following its formal inclusion on March 9th, sustained southbound capital inflows pushed average daily turnover from around HK$20 million to over HK$100 million, significantly optimizing the shareholder structure.
Additionally, sector-wide factors provided some lift, with two ADC preclinical studies disclosed ahead of the AACR annual meeting drawing attention to the company's innovative technology platform.
However, after April 16th, the Hong Kong healthcare sector entered a correction cycle, and market risk aversion towards high-risk assets increased.
This downward cycle can be divided into two phases.
The first phase, from April 16th to May 8th, was influenced by the broader sector correction and a lack of key new data.
The second phase, from May 11th to the present, was directly triggered by the approval of the company's H-share full circulation plan.
Understanding the Recent Pressure Points
On May 8th after the market closed, LEADS BIOLABS-B announced the implementation of its H-share full circulation plan, with formal exchange approval announced on May 14th.
The plan involves the conversion of 44.39 million non-tradable shares, increasing the secondary market float by 28.9%.
Compounding this, the company faces a significant early shareholder lock-up expiration on July 25th this year.
This involves 42 early shareholders, with 104 million shares becoming eligible for sale, representing 52.22% of the total shares and a market value of approximately HK$5.271 billion.
Notably, two significant custody movements occurred on June 4th and June 23rd.
On June 4th, shares worth HK$1.486 billion were deposited with the Hong Kong Securities Clearing Company, reducing a shareholder's stake by 59.44%.
On June 23rd, shares worth HK$369 million were deposited with Citibank.
In Hong Kong, depositing shares into the clearing system is a prerequisite for trading, so while such movements do not equate to an immediate sale, they are often viewed as preparation for potential selling.
Despite the company announcing on May 18th that its core asset, LBL-024, received approval in China for a Phase III clinical trial, this milestone failed to halt the stock's decline, highlighting strong bearish sentiment among holders regarding the upcoming share unlock.
Evaluating Fundamentals Amid the Downturn
For LEADS BIOLABS-B, the current price decline, whether driven by sector trends or the impending unlock, reflects investors' decisions based on prevailing market logic.
The market logic has shifted from simple event-driven trading to a phase of more refined, fundamentals-based pricing.
As a pre-revenue, pre-profit Chapter 18A company, LEADS BIOLABS-B is almost inevitably subject to a valuation discount under this logic.
The best assets such a company can present are its pipeline and cash reserves.
LEADS BIOLABS-B's most compelling asset is the commercial potential of its core product, LBL-024.
LBL-024 is a PD-L1/4-1BB bispecific antibody designed as a potential foundational IO 2.0 therapy with broad tumor potential, not just for a single small cancer indication.
It conditionally activates 4-1BB, aiming to relieve PD-1/PD-L1 mediated immunosuppression while enhancing T-cell activation for a synergistic anti-tumor effect.
It has demonstrated best-in-class/first-in-class potential across several solid tumors, including non-small cell lung cancer, small cell lung cancer, and biliary tract cancer.
From a commercialization timeline perspective, the key registrational clinical study for 3L+ EP-NEC completed enrollment last August.
The company plans to submit a pre-BLA application in Q2 and a BLA in Q3 this year, potentially leading to conditional approval as early as Q2-Q3 2027.
Regarding the crucial metric of cash reserves for a Chapter 18A company, LEADS BIOLABS-B held RMB 1.548 billion in cash and equivalents at the end of 2025.
This is considered sufficient to support the initial commercialization launch and fund R&D expenses for the next 3-4 years, providing a solid financial safety cushion.
Given this backdrop, if short-term pressures from sector trends and the share unlock are difficult to avoid entirely, a potential strategy could be to watch for signs of price stabilization and then consider a position based on the company's robust fundamentals, betting on a subsequent valuation rebound.
Comments